<DOC>
	<DOCNO>NCT02152007</DOCNO>
	<brief_summary>A study evaluate safety efficacy topical sirolimus treat plantar keratoderma adult PC . Subjects may receive either placebo treatment least 1 foot receive topical sirolimus time . For certain phase study treatment assignment right leave foot randomize double blind fashion . Blood level test systemic absorption sirolimus . Other safety efficacy measure take 39-week study duration . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Topical Sirolimus Treatment Pachyonychia Congenita ( PC )</brief_title>
	<detailed_description />
	<mesh_term>Nails , Malformed</mesh_term>
	<mesh_term>Pachyonychia Congenita</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subjects must : Be capable understand purpose risk study sign write Informed Consent Form ( ICF ) Be male female â‰¥ 16 year age time screen visit Have confirm diagnosis PC genotyping ( e.g. , familial ) clinically correlate painful keratoderma . Have roughly symmetrical callus similar severity plantar surface foot Women childbearing potential must negative serum pregnancy test Subjects , whether male female , reproductive potential sexually active must agree use doublebarrier contraception method A Subject follow criterion eligible inclusion study : Use investigational drug within 30 day screen visit and/or recover side effect prior investigational drug procedure affect area ( e.g. , biopsy ) Significant condition dermatologic treatment area trauma , nonhealing chronic wound Pregnant nursing ( lactate ) female , positive serum pregnancy test Active infection either systemic local near site treatment require chronic prolong use antimicrobial agent Known immunodeficiency include : Hepatitis A ; Hepatitis B ; Hepatitis C ; Human Immunodeficiency Virus ( HIV ) Prior Current Treatment Unable discontinue drug know either inducer inhibitor CYP3A4/5 enzymes Unable discontinue drug know Pglycoprotein inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>pachyonychia congenita</keyword>
</DOC>